Literature DB >> 1711222

The p15 carboxyl-terminal proteolysis product of the human immunodeficiency virus type 1 reverse transcriptase p66 has DNA polymerase activity.

P Hafkemeyer1, E Ferrari, J Brecher, U Hübscher.   

Abstract

The reverse transcriptase of human immunodeficiency virus type 1 is a heterodimeric protein consisting of two polypeptides with masses of 66 and 51 kDa and has, as a second enzymatic activity, RNase H activity. The 66-kDa polypeptide can be cleaved by the virus-encoded protease to yield polypeptides of 51 and 15 kDa. The latter has been characterized as possessing RNase H activity [Hansen, J., Schultze, T., Mellert, W. & Moelling, K. (1988) EMBO J. 7, 239-243]. We have purified simultaneously the heterodimeric reverse transcriptase/RNase H containing the 66/51-kDa polypeptides and the 15-kDa RNase H from Escherichia coli containing the expression vector pJS 3.7 by a procedure including chromatography on DEAE-cellulose, phosphocellulose, and heparin-Sepharose. Two RNase H and reverse transcriptase peaks were separated on phosphocellulose, one coinciding with the heterodimeric protein and the other with the 15-kDa protein. On the basis of the following findings it appears that the 15-kDa polypeptide has both RNase H and reverse transcriptase activities: (i) it copurified with both activities; (ii) it functioned as a reverse transcriptase in an in situ assay after SDS/polyacrylamide gel electrophoresis; (iii) polyclonal antibodies raised against the 66-kDa polypeptide reacted in immunoblots exclusively with a 15-kDa polypeptide, reacted in immunoblots exclusively with a 15-kDa polypeptide, while no immunoreactive bands in the range of 51-66 kDa were seen in the 15-kDa polypeptide preparation; (iv) the p15 and the p66/51 reverse transcriptase could be quantitatively pelleted in an enzymatically active form only when antibodies specific for the p66 carboxyl terminus were used; and (v) the p15 protein had bona fide properties of a reverse transcriptase and could enzymatically synthesize a high molecular weight, alkali-resistant product. The two reverse transcriptases appear to have different behaviors on various template/primer systems tested. Conceivably different forms of human immunodeficiency virus type 1 reverse transcriptases might be used in individual steps of (+)- and (-)-strand replication.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711222      PMCID: PMC51852          DOI: 10.1073/pnas.88.12.5262

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

Review 1.  Eukaryotic DNA replication. Enzymes and proteins acting at the fork.

Authors:  P Thömmes; U Hübscher
Journal:  Eur J Biochem       Date:  1990-12-27

2.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

3.  Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural DNA.

Authors:  J Weber; F Grosse
Journal:  Nucleic Acids Res       Date:  1989-02-25       Impact factor: 16.971

4.  Human immunodeficiency virus reverse transcriptase-associated RNase H activity.

Authors:  M C Starnes; Y C Cheng
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157

5.  A conserved 3'----5' exonuclease active site in prokaryotic and eukaryotic DNA polymerases.

Authors:  A Bernad; L Blanco; J M Lázaro; G Martín; M Salas
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

Review 6.  Progress toward molecular biology of DNA polymerase beta.

Authors:  S Wilson; J Abbotts; S Widen
Journal:  Biochim Biophys Acta       Date:  1988-02-28

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Two forms of DNA polymerase delta from mouse cells. Purification and properties.

Authors:  M Goulian; S M Herrmann; J W Sackett; S L Grimm
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

9.  Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus.

Authors:  M M Lightfoote; J E Coligan; T M Folks; A S Fauci; M A Martin; S Venkatesan
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

10.  Identification and characterization of HIV-specific RNase H by monoclonal antibody.

Authors:  J Hansen; T Schulze; W Mellert; K Moelling
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598

View more
  5 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  The large subunit of HIV-1 reverse transcriptase interacts with beta-actin.

Authors:  M Hottiger; K Gramatikoff; O Georgiev; C Chaponnier; W Schaffner; U Hübscher
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

3.  Characterization of HIV-1 reverse transcriptase with antibodies indicates conformational differences between the RNAse H domains of p 66 and p 15.

Authors:  A M Szilvay; S Nornes; A Kannapiran; B I Haukanes; C Endresen; D E Helland
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  Recognition by viral and cellular DNA polymerases of nucleosides bearing bases with nonstandard hydrogen bonding patterns.

Authors:  J Horlacher; M Hottiger; V N Podust; U Hübscher; S A Benner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

5.  Differential discrimination of DNA polymerase for variants of the non-standard nucleobase pair between xanthosine and 2,4-diaminopyrimidine, two components of an expanded genetic alphabet.

Authors:  M J Lutz; H A Held; M Hottiger; U Hübscher; S A Benner
Journal:  Nucleic Acids Res       Date:  1996-04-01       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.